fda social media guidelines - introduction
DESCRIPTION
Slides for a School of Dentistry Bootcamp, Februrary 10, 2010TRANSCRIPT
![Page 1: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/1.jpg)
Introduction to the FDASM
PF Anderson, Emerging Technologies Librarian for the Health Sciences, University of Michigan
School of Dentistry Bootcamp, February 10, 2010
![Page 2: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/2.jpg)
What is #FDASM?
![Page 3: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/3.jpg)
![Page 4: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/4.jpg)
FDA’s Stated PurposeThis hearing is intended to provide an opportunity for broad public participation and comment concerning Internet promotion of FDA-regulated medical products, including human and animal prescription drugs and biologics and medical devices. Please note that this hearing does not address nonprescription drug promotion. FDA is particularly interested in hearing views from the public as to how expanding Web 2.0 technologies may be used to promote medical products to both health care professionals and consumers in a truthful, nonmisleading, and balanced manner. In addition, FDA is seeking public comment on Internet adverse event reporting.
![Page 5: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/5.jpg)
FDA’s Purpose: Main PointsInternet promotion of FDA-regulated medical products
human/animal prescription drugs biologics medical devices
does NOT address nonprescription drug promotion
Web 2.0 use to promote medical products
to both health care professionals and consumers in a truthful, nonmisleading, and balanced manner
Internet adverse event reporting
![Page 6: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/6.jpg)
Our Question
![Page 7: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/7.jpg)
Who, What, Where, WhyWho
is allowed to say What
to Whom
regarding health information
Where in online spaces and social media?
Are Why & When & How part of the question/answer?
![Page 8: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/8.jpg)
Main Questions Addressed
![Page 9: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/9.jpg)
1. Accountability
2. Regulatory requirements best practices
3. Corrective information
4. Links
5. Adverse event reporting
![Page 10: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/10.jpg)
1. For what online communications are manufacturers, packers, or distributors accountable?
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
![Page 11: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/11.jpg)
2. How can manufacturers, packers, or distributors fulfill regulatory requirements (e.g., fair balance, disclosure of indication and risk information, postmarketing submission requirements) in their Internet and social media promotion, particularly when using tools that are associated with space limitations and tools that allow for real-time communications (e.g., microblogs, mobile technology)?
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
![Page 12: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/12.jpg)
3. What parameters should apply to the posting of corrective information on Web sites controlled by third parties?
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
![Page 13: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/13.jpg)
4. When is the use of links appropriate?
5. Questions specific to Internet adverse event reporting
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
![Page 14: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/14.jpg)
FDASM Resources
![Page 15: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/15.jpg)
![Page 16: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/16.jpg)
![Page 17: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/17.jpg)
![Page 18: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/18.jpg)
![Page 19: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/19.jpg)
Wordle from Transcripts
![Page 20: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/20.jpg)
Highlights from November Forum
![Page 21: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/21.jpg)
1. Outbound Links
Who is responsible if the target link changes content or location?
Who should be required to use in-between page warning consumer they are leaving the site? What about groups that don’t have the skills or resources necessary to do so?
![Page 22: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/22.jpg)
2. Semi-private conversations
Social media allows conversations and questions between private individuals in public spaces.
![Page 23: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/23.jpg)
3. Spurious content
Who decides what is good and what is not?
Who should be held accountable for the quality of the information provided?
What should be asked of those who provide questionable content?
![Page 24: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/24.jpg)
![Page 25: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/25.jpg)
4. Off-Label Use
When is emerging research beneficial or dangerous to a healthcare consumer?
Who decides?
Should conversations on off-label use be supported, discouraged or managed?
![Page 26: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/26.jpg)
5. European Precedents
Title VIII, Advertising, Article 86 (Denmark)”Directive 2001/83/EC on the Community code relating to medicinal products for human use” in conflict with “The European Convention for the protection of human rights and fundamental freedoms”
The European Court of Justice: Third-party statements about medicines may be advertising: http://www.dkma.dk/1024/visUKLSArtikelBred.asp?artikelID=15472&print=true
Digital Economy Bill (in progress, UK)
Clause 11
![Page 27: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/27.jpg)
![Page 28: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/28.jpg)
Maybe, instead of banning all kinds of opinions on particular product, one should think of a better way to distinguish independent journalism from mere marketing strategies. The question is how?
![Page 29: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/29.jpg)
![Page 30: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/30.jpg)
Context: Social Media Use Examples
![Page 31: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/31.jpg)
![Page 32: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/32.jpg)
![Page 33: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/33.jpg)
![Page 34: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/34.jpg)
![Page 35: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/35.jpg)
![Page 36: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/36.jpg)
![Page 37: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/37.jpg)
![Page 38: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/38.jpg)
![Page 39: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/39.jpg)
Things You Can Do NOW
![Page 40: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/40.jpg)
Think about your concerns and hopes for the forthcoming guidelines. Register your comments NOW.
FDA will have a second 90-day comment period after the initial guidelines are proposed.
![Page 41: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/41.jpg)
![Page 42: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/42.jpg)
![Page 43: FDA Social Media Guidelines - Introduction](https://reader034.vdocuments.site/reader034/viewer/2022042714/5552c41cb4c90581158b4991/html5/thumbnails/43.jpg)
What do YOU want the FDA to do?